Citations

Showing 10 of 108119 citations.

VP2: Mesenchymal Stem Cells and Local Tacrolimus Delivery Synergistically Enhance Neurite Extension
Saffari, Tara Sara, Saffari, Tiam M. , Chan, Katelyn, Chan, Katelyn, Borschel, Gregory Howard , Shin, Alexander Y.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | January 5, 2022 | Volume: 10 | Issue: 1S | Pages: 13-13

10.1097/01.gox.0000817740.52584.33 Get It

Disparities in Lung Protective Ventilation in the United States
Malnoske, Michelle , Quill, Caroline M., Pietropaoli, Anthony P. , Barwise, Amelia

Mayo Clinic

No container title available | January 5, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1217783/v1 Get It

Abstract Background: Lung-protective ventilation is often used in critically ill patients with acute respiratory failure, including those without acute respiratory distress syndrome. While disparities exist in the delivery of critical care based on gender, race, and insurance status, it is unknown whether there are disparities in the use of lung-protective ventilation. The objective of our study was to determine whether gender-, racial / ethnic-, or insurance status-based disparities exist in the use of lung-protective ventilation for critically ill mechanically ventilated patients in the United States (U.S.).Methods: This was a secondary data analysis of the U.S. Critical Illness and Injury Trials Group Critical Illness Outcomes Study, a prospective multi-center cohort study conducted from 2010 - 2012. The dependent variable of interest was the proportion of patients receiving tidal volume > 8 mL/kg predicted body weight (PBW). The independent variables of interest were gender, insurance status, and race / ethnicity. Results: Our primary analysis included 1,595 mechanically ventilated patients from 59 intensive care units (ICUs) in the U.S. Women were more likely to receive tidal volumes > 8 ml/kg PBW than men (odds ratio [OR] = 3.25, 95% confidence interval [CI] = 2.58 – 4.09), though this relationship was substantially weakened after adjusting for gender differences in height (OR = 1.26 95% CI = 0.94 – 1.71). The underinsured were significantly more likely to receive tidal volume > 8 ml/kg PBW than the insured in multivariable analysis (odds ratio = 1.54, 95% confidence interval = 1.16 – 2.04). The prescription of > 8 ml/kg PBW tidal volume did not differ by racial or ethnic categories. Conclusions: In this prospective nationwide cohort of critically ill mechanically ventilated patients, women and the underinsured were less likely than their comparators to receive lung protective ventilation, with no apparent differences based on race / ethnicity alone. Differences in height between men and women do not fully explain this disparity. Future research should evaluate whether implicit bias affects tidal volume choice and other management decisions in critical care.
Isocitrate Dehydrogenase–Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes
Wintheiser, Grant , Zemla, Tyler, Shi, Qian, Tran, Nguyen H. , Prasai, Kritika, Tella, Sri Harsha, Mody, Kabir , Ahn, Daniel, Borad, Mitesh J. , Bekaii‐Saab, Tanios , Shi, Qian , Tran, Nguyen , Borad, Mitesh J , Mahipal, Amit , Shi, Qian , Wintheiser, Grant A , Bekaii-Saab, Tanios S , Zemla, Tyler, Shi, Qian, Prasai, Kritika, Tella, Sri Harsha, Mody, Kabir , Ahn, Daniel

Mayo Clinic

JCO Precision Oncology | January 5, 2022 | Volume: No volume available | Issue: 6 | Pages: No page available

10.1200/po.21.00156 | PMID 35005992 Get It

Purpose Clinical-pathologic features and natural history of patients with isocitrate dehydrogenase ( IDH)-mutant intrahepatic cholangiocarcinoma (CCA) are not well characterized. Here, we sought to describe the natural history, clinical phenotype, and prognostic impact of advanced, IDH-mutated CCA. METHODS We conducted a multicentric, retrospective analysis of patients with IDH-mutated (IDH1 or IDH2) CCA between 2010 and 2020. Median overall survival (OS) and progression-free survival (PFS) analyses were performed using the Kaplan-Meier method. Chi-square test was used to analyze disease control rate (DCR) and overall response rate (ORR). Matched controls were used for comparing survival between patients with and without IDH mutations (mIDH). RESULTS Sixty-five patients with IDH-mutated CCA were included. All patients had intrahepatic CCA. On first-line chemotherapy, median OS and median PFS were 21.2 months and 8.3 months, respectively. Notably, median OS (32.4 v 19.5 months, P = .12) and PFS (18.0 v 8.0 months, P = .12) were not significantly affected by disease status at presentation (locally advanced v metastatic, respectively). Median OS was significantly longer in patients with mIDH (21.2 v 10.5 months; P < .01). First-line gemcitabine-containing regimens had a significantly higher DCR and ORR than non–gemcitabine-containing regimens (DCR: 75% v 33%, P = .01; ORR: 39% v 0%, P = .02). In patients receiving IDH inhibitor therapy, median PFS was 4.6 months with a DCR of 29%. CONCLUSION CCA with m IDH confers a unique subtype resulting in a better survival compared with that of counterparts. IDH inhibitors represent a promising therapeutic option in later lines of therapy in this subgroup.
Cocaine increases stimulation-evoked serotonin efflux in the nucleus accumbens
Yuen, Jason , Goyal, Abhinav , Rusheen, Aaron E. , Berk, Michael , Kim, Jee Hyun , Bennet, Kevin E. , Lee, Kendall H. , Shin, Hojin , Shin, Hojin , Berk, Michael , Kouzani, Abbas Z. , Tye, Susannah J. , Blaha, Charles D. , Oh, Yoonbae

Mayo Clinic

Journal of Neurophysiology | January 5, 2022 | Volume: 127 | Issue: 3 | Pages: 714-724

10.1152/jn.00420.2021 | PMID 34986049 Get It

Serotonin plays a vital role in drug addiction. Here, using N-shaped fast-scan cyclic voltammetry, we demonstrated the effect of cocaine on the phasic release of serotonin at the nucleus accumbens core. To the best of our knowledge, this has not previously been elucidated. Our results not only reinforce the role of serotonin in the mechanism of action of cocaine but also help to fill a gap in our knowledge and provide a baseline for future studies in cocaine addiction.
Differential Transcriptomic Profiles in Canine Intestinal Organoids Following Lipopolysaccharide Stimulation
Sahoo, Dipak Kumar , Chandra, Lawrance C., Jergens, Albert E. , Atherly, Todd, Bourgois‐Mochel, Agnes, Ellinwood, Matthew, Snella, Elizabeth , Martin, Martin, Mochel, Jonathan P. , Sahoo, Dipak K , Mochel, Jonathan P , Borcherding, Dana C. , Severin, Andrew Josef , Allenspach, Karin

Mayo Clinic

No container title available | January 5, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-967308/v1 Get It

Abstract Lipopolysaccharide (LPS) is associated with chronic intestinal inflammation and promotes intestinal cancer progression in the gut. While the interplay between LPS and intestinal immune cells has been well characterized, little is known about LPS and intestinal epithelium interactions. In this study, we explored the differential effect of LPS on proliferation and the transcriptome in 3D enteroids/colonoids obtained from dogs with naturally occurring gastrointestinal (GI) diseases, such as Inflammatory Bowel Disease (IBD) and GI mast cell tumor. The study objective was to analyze LPS-induced modulation of signaling pathways involving the intestinal epithelia and critical to colorectal cancer development in the context of IBD or a tumor microenvironment. While LPS incubation resulted in a pro-cancer gene expression pattern and stimulated proliferation of IBD enteroids and colonoids, down-regulation of several cancer-associated genes like CRYZL1, Gpatch4, SLC7A1, ATP13A2, and ZNF358 was also observed in tumor enteroids. Genes participating in porphyrin metabolism (CP), thiamine and purine metabolism (TAP2, EEF1A1), arachidonic acid, and glutathione metabolism (GPX1) exhibited a similar pattern of altered expression between IBD enteroids and IBD colonoids following LPS stimulation. In contrast, genes involved in anion transport, transcription and translation, apoptotic processes, and regulation of adaptive immune responses showed opposite expression patterns between IBD enteroids and colonoids following LPS treatment. In brief, the cross-talk between LPS/TLR4 signal transduction pathway and several metabolic pathways, such as fatty acid degradation and biosynthesis, and purine, thiamine, arachidonic acid, and glutathione metabolism, may be important in driving chronic intestinal inflammation and intestinal carcinogenesis.
Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management
Patnaik, Mrinal M. , Tefferi, Ayalew

Mayo Clinic

American Journal of Hematology | January 5, 2022 | Volume: 97 | Issue: 3 | Pages: 352-372

10.1002/ajh.26455 | PMID 34985762 Get It

AbstractDisease OverviewChronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes and myeloproliferative neoplasms, with an inherent risk for leukemic transformation (~15% over 3–5 years).DiagnosisDiagnosis is based on the presence of sustained (>3 months) peripheral blood monocytosis (≥1 × 109/L; monocytes ≥10%), usually with accompanying bone marrow dysplasia. Clonal cytogenetic abnormalities occur in ~30% of patients, while >90% have somatic gene mutations. Mutations involving TET2 (~60%), SRSF2 (~50%), ASXL1 (~40%), and the oncogenic RAS pathway (~30%) are frequent, while the presence of ASXL1 and DNMT3A mutations and the absence of TET2 mutations negatively impact overall survival.Risk‐StratificationMolecularly integrated prognostic models include the Groupe Français des Myélodysplasies, Mayo Molecular Model (MMM), and the CMML specific prognostic model. Risk factors incorporated into the MMM include presence of truncating ASXL1 mutations, absolute monocyte count >10 × 109/L, hemoglobin <10 g/dL, platelet count <100 × 109/L, and the presence of circulating immature myeloid cells. The MMM stratifies CMML patients into four groups: high (≥3 risk factors), intermediate‐2 (2 risk factors), intermediate‐1 (1 risk factor), and low (no risk factors), with median survivals of 16, 31, 59, and 97 months, respectively.Risk‐adapted therapyHypomethylating agents such as 5‐azacitidine and decitabine are commonly used, with overall response rates of ~40%–50% and complete remission rates of ~7%–17%; with no impact on mutational allele burdens. Allogeneic stem cell transplant is the only potentially curative option but is associated with significant morbidity and mortality.
New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options
Tsao, Anne S. , Pass, Harvey I., Rimner, Andreas , Mansfield, Aaron S. , Mansfield, Aaron S , Tsao, Anne S. , Pass, Harvey I., Rimner, Andreas

Mayo Clinic

Journal of Clinical Oncology | January 5, 2022 | Volume: 40 | Issue: 6 | Pages: 681-692

10.1200/jco.21.01567 | PMID 34985934 Get It

Malignant pleural mesothelioma (MPM) is a rare malignancy with few treatment options. Recent advances have led to US Food and Drug Administration approvals and changes in the standard of care with a novel biomedical device approved for use with platinum-pemetrexed, and also for immunotherapy agents to be included as a frontline treatment option in unresectable disease. Although predictive biomarkers for systemic therapy are not currently in use in clinical practice, it is essential to correctly identify the MPM histology to determine an optimal treatment plan. Patients with nonepithelioid MPM may have a greater magnitude of benefit to dual immunotherapy checkpoint inhibitors and this regimen should be preferred in the frontline setting for these patients. However, all patients with MPM can derive benefit from immunotherapy treatments, and these agents should ultimately be used at some point during their treatment journey. There are ongoing studies in the frontline unresectable setting that may further define the frontline therapy space, but a critical area of research will need to focus on the immunotherapy refractory population. This review article will describe the new developments in the areas of biology with genomics and chromothripsis, and also focus on updates in treatment strategies in radiology, surgery, radiation, and medical oncology with cellular therapies. These recent innovations are generating momentum to find better therapies for this disease.
Liquid biopsy in gliomas: A RANO review and proposals for clinical applications
Mellinghoff, Ingo K. , Warren, Katherine E. , Ahluwalia, Manmeet S. , Galanis, Evanthia , Jaeckle, Kurt A. , Seoane, Joan , Thon, Niklas , Umemura, Yoshie , Weller, Michael , Bent, Martin J. van den , Vogelbaum, Michael A. , Chang, Susan M. , Wen, Patrick Y. , Soffietti, Riccardo , Galanis, Evanthia , Weller, Michael , van den Bent, Martin J , Umemura, Yoshie , Ahluwalia, Manmeet S , Mellinghoff, Ingo K , Soffietti, Riccardo , Bettegowda, Chetan , Groot, John de , Gilbert, Mark R. , Rhun, Émilie Le , Rudà, Roberta , Chang, Susan Marina , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | January 5, 2022 | Volume: 24 | Issue: 6 | Pages: 855-871

10.1093/neuonc/noac004 | PMID 34999836 Get It

Abstract Background There is an extensive literature highlighting the utility of blood-based liquid biopsies in several extracranial tumors for diagnosis and monitoring. Methods The RANO (Response Assessment in Neuro-Oncology) group developed a multidisciplinary international Task Force to review the English literature on liquid biopsy in gliomas focusing on the most frequently used techniques, that is circulating tumor DNA, circulating tumor cells, and extracellular vesicles in blood and CSF. Results ctDNA has a higher sensitivity and capacity to represent the spatial and temporal heterogeneity in comparison to circulating tumor cells. Exosomes have the advantages to cross an intact blood-brain barrier and carry also RNA, miRNA, and proteins. Several clinical applications of liquid biopsies are suggested: to establish a diagnosis when tissue is not available, monitor the residual disease after surgery, distinguish progression from pseudoprogression, and predict the outcome. Conclusions There is a need for standardization of biofluid collection, choice of an analyte, and detection strategies along with rigorous testing in future clinical trials to validate findings and enable entry into clinical practice.
Faculty Opinions recommendation of Obesity in pregnancy.
Sviggum, Hans P.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | January 5, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.740059386.793590691 Get It